Enterprise Value

718.8M

Cash

398.6M

Avg Qtr Burn

-37.74M

Short % of Float

6.43%

Insider Ownership

29.99%

Institutional Own.

73.09%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details
GIST (Gastrointestinal stromal tumors) (fourth-line)

Approved

Quarterly sales

Vimseltinib (DCC-3014) (CSF1R inhibitor) Details
Tenosynovial Giant Cell Tumors, Cancer

Phase 3

Data readout

Qinlock (Ripretinib) Details
Gastrointestinal stromal tumors

Phase 3

Initiation

Phase 1/2

Update

Phase 1

Initiation

DCC-3116 (Inhibitor of ULK)+ripretinib Details
Solid tumor/s, Gastrointestinal stromal tumors

Phase 1

Initiation

Failed

Discontinued